Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $26.72 Million |
|---|---|
| Enterprise Value | $16.87 Million |
| Earnings per Share | $- |
| Beta | -0.17 |
| Outstanding Shares | - |
| P/E Ratio | -0.37 |
|---|---|
| PEG | -0.74 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.55 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.